ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Exscientia, a specialist in artificial intelligence (AI) for drug discovery with its own drug pipeline, has closed a $225 million financing round led by SoftBank Vision Fund 2 with investment from Novo Holdings. Exscientia received an additional $300 million equity commitment from SoftBank. The company has advanced two AI-designed drug candidates into development, including a therapy for obsessive-compulsive disorder developed with Sumitomo Dainippon Pharma.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X